BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28615361)

  • 1. Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
    Ross SJ; Revenko AS; Hanson LL; Ellston R; Staniszewska A; Whalley N; Pandey SK; Revill M; Rooney C; Buckett LK; Klein SK; Hudson K; Monia BP; Zinda M; Blakey DC; Lyne PD; Macleod AR
    Sci Transl Med; 2017 Jun; 9(394):. PubMed ID: 28615361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
    Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
    Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
    Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
    Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
    Hong D; Kurzrock R; Kim Y; Woessner R; Younes A; Nemunaitis J; Fowler N; Zhou T; Schmidt J; Jo M; Lee SJ; Yamashita M; Hughes SG; Fayad L; Piha-Paul S; Nadella MV; Mohseni M; Lawson D; Reimer C; Blakey DC; Xiao X; Hsu J; Revenko A; Monia BP; MacLeod AR
    Sci Transl Med; 2015 Nov; 7(314):314ra185. PubMed ID: 26582900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
    Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
    Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer.
    Kitai H; Ebi H
    Small GTPases; 2017 Jul; 8(3):172-176. PubMed ID: 27392325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides.
    Wang D; Wang Q; Wang Y; Chen P; Lu X; Jia F; Sun Y; Sun T; Zhang L; Che F; He J; Lian L; Morano G; Shen M; Ren M; Dong SS; Zhao JJ; Zhang K
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2113180119. PubMed ID: 35858356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
    Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
    J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
    Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
    Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin.
    Ma Y; Guo FC; Wang W; Shi HS; Li D; Wang YS
    Mol Med Rep; 2013 Sep; 8(3):763-8. PubMed ID: 23877793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.